Aldeyra Therapeutics, Inc (NASDAQ:ALDX - Get Free Report)'s stock price crossed below its 50 day moving average during trading on Friday . The stock has a 50 day moving average of $5.07 and traded as low as $4.83. Aldeyra Therapeutics shares last traded at $4.94, with a volume of 362,371 shares trading hands.
Aldeyra Therapeutics Stock Down 1.6 %
The company has a debt-to-equity ratio of 0.18, a quick ratio of 6.80 and a current ratio of 6.80. The firm has a 50-day moving average price of $5.06 and a 200-day moving average price of $4.80.
Aldeyra Therapeutics (NASDAQ:ALDX - Get Free Report) last posted its quarterly earnings data on Thursday, November 7th. The biotechnology company reported ($0.25) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.25). Equities analysts expect that Aldeyra Therapeutics, Inc will post -0.92 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Aldeyra Therapeutics
A number of hedge funds have recently modified their holdings of the stock. Bank of New York Mellon Corp increased its position in Aldeyra Therapeutics by 21.7% in the second quarter. Bank of New York Mellon Corp now owns 195,722 shares of the biotechnology company's stock worth $648,000 after buying an additional 34,885 shares during the last quarter. Panagora Asset Management Inc. purchased a new stake in Aldeyra Therapeutics in the 2nd quarter worth about $200,000. Rhumbline Advisers raised its stake in Aldeyra Therapeutics by 20.1% in the 2nd quarter. Rhumbline Advisers now owns 76,981 shares of the biotechnology company's stock valued at $255,000 after acquiring an additional 12,907 shares during the period. Laidlaw Wealth Management LLC lifted its holdings in Aldeyra Therapeutics by 32.6% during the second quarter. Laidlaw Wealth Management LLC now owns 16,875 shares of the biotechnology company's stock valued at $56,000 after purchasing an additional 4,150 shares during the last quarter. Finally, PFG Investments LLC bought a new position in Aldeyra Therapeutics during the second quarter worth about $1,312,000. Institutional investors own 59.71% of the company's stock.
About Aldeyra Therapeutics
(
Get Free Report)
Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.
See Also
Before you consider Aldeyra Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aldeyra Therapeutics wasn't on the list.
While Aldeyra Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
